Related Experiment Video

Updated: Jul 5, 2026

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

c-Met targeted therapy of cholangiocarcinoma

Matei-P Socoteanu1, Frank Mott, Gianfranco Alpini

  • 1Scott & White Cancer Research Institute, Temple, Texas 76502, USA.

World Journal of Gastroenterology
|May 22, 2008
PubMed

Insights

Cholangiocarcinoma (bile duct cancer) treatment remains difficult. Targeting the c-Met pathway, crucial in cancer development, offers a promising strategy for novel therapies against this challenging disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Cholangiocarcinoma (CCA) presents significant treatment challenges, especially in advanced or unresectable stages.
  • Current systemic therapies for CCA have shown limited efficacy in clinical trials.
  • Understanding the molecular drivers of CCA is essential for developing targeted treatments.

Purpose of the Study:

  • To review the role of the c-Met/hepatocyte growth factor (HGF) pathway in cholangiocarcinoma development.
  • To explore the c-Met signaling cascade as a potential therapeutic target for CCA.
  • To assess current and future c-Met-targeted agents for CCA treatment.

Main Methods:

  • Literature review of studies on cholangiocarcinoma molecular carcinogenesis.
  • Analysis of the c-Met/HGF pathway's involvement in CCA.
  • Review of existing and potential c-Met-targeting drugs.

Main Results:

  • The c-Met/HGF pathway plays a significant role in the molecular development of cholangiocarcinoma.
  • Targeting the c-Met cascade presents a viable strategy for novel CCA therapies.
  • Several c-Met-targeting agents are under investigation or in development.

Conclusions:

  • Targeting the c-Met pathway holds promise for improving cholangiocarcinoma treatment outcomes.
  • Further development and clinical evaluation of c-Met inhibitors are warranted for CCA.
  • Molecular understanding is key to advancing targeted therapies for bile duct cancer.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...